AOD-9604
aka Anti-Obesity Drug 9604
AOD-9604 in brief
AOD-9604 (Anti-Obesity Drug 9604) is a fragment of human growth hormone (177-191) claimed to have fat-burning effects without GH side effects. Amino Axiom rates its evidence base strong, drawing on 10 PubMed results (10 human studies). It is filed under Weight Loss in the Amino Axiom compound index. This summary reflects published research and is not medical advice.
Research data
Open any panel for the full data
Third-party creator videos and discussion, surfaced for research context. Amino Axiom does not endorse creator claims.
Long-form breakdowns
8 videosShort-form clips
5 clipsFull Research Data
Overview
AOD-9604 is a synthetic analog of the lipolytic domain of human growth hormone (hGH 177-191). It was originally developed as an anti-obesity drug. Animal studies showed lipolytic effects, but human trials failed to show significant weight loss. It does not raise IGF-1 levels.
PubMed results: 10 · Human studies: 10 · Animal studies: 10
Dosing Ranges
Ranges reflect protocols studied in published research and animal-model extrapolation. Presented for research purposes only, not a recommendation or instruction for human use.
- Subcutaneous — standard range 300-600 mcg, Once daily
Half-Life
Unknown in humans (low confidence)
Observed Benefits
- Lipolytic domain of hGH fragment research (Strong preclinical): AOD-9604 is a synthetic analog of the C-terminal lipolytic region of human growth hormone (hGH 177-191); animal studies reported enhanced lipolysis and reduced lipogenesis without classic GH anabolic signaling.
- Minimal IGF-1 elevation relative to intact GH (Moderate clinical): Research indicates AOD-9604 does not meaningfully raise circulating IGF-1 levels, distinguishing its endocrine profile from intact growth hormone in clinical observations.
- Obesity drug development history (Limited): Human trials of AOD-9604 as an anti-obesity candidate failed to demonstrate significant weight loss, so clinical body-composition efficacy remains unproven despite earlier preclinical signals.
Side Effects
- Generally well-tolerated in trial reports — Mild, Not established. Published clinical development for obesity reported a relatively favorable tolerability profile overall, without a widely characterized unique toxicity signature.
- Injection-site reactions — Mild, Anecdotal. Local injection-site findings are discussed in peptide research settings; frequency specific to AOD-9604 is not firmly established in large post-marketing datasets.
Contraindications
- Known hypersensitivity to growth-hormone fragment analogs (Theoretical / Preclinical): Structural relation to hGH C-terminal sequences supports theoretical caution where prior hypersensitivity is documented.
- Pregnancy (Theoretical / Preclinical): Insufficient reproductive safety data for AOD-9604 support theoretical exclusion of pregnancy research contexts.
Storage
Lyophilized (powder): Refrigerated (2-8°C), Up to 24 months. Light sensitive: yes, store dark
Reconstituted (solution): Refrigerated (2-8°C), 4-6 weeks. Solvent: Bacteriostatic water